Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI).
Anne Kristine AnstensrudSindre WoxholtKapil SharmaKaspar BrochBjørn BendzSvend AakhusThor UelandBrage H AmundsenJan Kristian DamåsEinar HoppOla KlevelandKnut Haakon StensæthAnders OpdahlNils-Einar KløwIngebjørg SeljeflotGeir Øystein AndersenRune WisethPål AukrustLars GullestadPublished in: Open heart (2019)
Clinicaltrials.gov, identifier NCT03004703.
Keyphrases
- st elevation myocardial infarction
- percutaneous coronary intervention
- clinical trial
- rheumatoid arthritis
- phase iii
- study protocol
- phase ii
- left ventricular
- juvenile idiopathic arthritis
- st segment elevation myocardial infarction
- rheumatoid arthritis patients
- acute coronary syndrome
- coronary artery disease
- open label
- randomized controlled trial
- heart failure
- atrial fibrillation
- disease activity